Ra Capital Management, L.P. Kinnate Biopharma Inc. Transaction History

Ra Capital Management, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $5.19 Million - $12.1 Million	671,092 Added 18.68%	4,264,144 $48 Million
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $131 Million - $163 Million	3,593,052 New	3,593,052 $143 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.